Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Pharmacological studies on the action mechanism of ingenol mebutate against pancreatic cancer cell lines.

PROVIDER: PRJDB14478 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR412424_1.fastq.gz	Fastqsanger.gz
	DRR412424_2.fastq.gz	Fastqsanger.gz
	DRR412425_1.fastq.gz	Fastqsanger.gz
	DRR412425_2.fastq.gz	Fastqsanger.gz
	DRR412426_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Ingenol mebutate induces profound inflammatory and wound healing responses in uninvolved and actinic keratosis skin

Project description:We studied the transcriptomic profile of actinic keratosis (AK) skin compared to matched samples from uninvolved skin (US) before and after treatment with ingenol mebutate gel. We found that AK has a distinct mRNA profile that separates it from uninvolved skin. In particular, numerous genes associated with epidermal development and keratinocyte differentiation, such as LCE3D, SPRR1A, PI3 and several genes in the keratin family were highly expressed in AK0 skin, but not in US0, in line with the hyperkeratosis characteristic for AK. Topical application of ingenol mebutate had a profound effect on the gene expression profile, and interestingly, many more genes were affected in US than in AK. Enrichment analysis revealed that the main responses to ingenol mebutate treatment of both US and AK were inflammatory response, response to wounding, and wound healing. 30 skin biopsies were analysed; 5 from each of 6 AK patients. Before initiation of treatment, baseline biopsies were taken from one AK lesion (AK0) and from uninvolved skin (US0). A third biopsy was taken after day 1 application of ingenol mebutate from one AK lesion (AK1). The fourth and fifth biopsies were obtained one day after the second topical application with ingenol mebutate from an AK lesion (AK2) and from uninvolved skin (US2), respectively.

2016-03-31 | E-GEOD-63107 | biostudies-arrayexpress

Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel

Project description:Actinic keratosis is a common skin disease that may progress to invasive squamous cell carcinoma. Ingenol mebutate has demonstrated efficacy in field treatment of actinic keratosis. However, molecular mechanisms on ingenol mebutate response are not yet fully understood.

2020-05-18 | GSE142108 | GEO

Ingenol mebutate induces profound inflammatory and wound healing responses in uninvolved and actinic keratosis skin

2016-03-31 | GSE63107 | GEO

E-GEOD-12513

Project description:Genes regulated by AGR2 in pancreatic cancer cell lines FA6 and MiaPaCa2

2025-01-24 | E-GEOD-12513 | ExpressionAtlas

Homo sapiens

Project description:Differential gene expression after ingenol mebutate (IM) treatment

| PRJNA267521 | ENA

Rescue of T cell exhaustion by ingenol mebutate

Project description:Rescue of T cell exhaustion by ingenol mebutate

| PRJNA540148 | ENA

E-GEOD-45757

Project description:Expression Data from 22 human pancreatic cancer cell lines grown in triplicates +/- MEK inhibitor CI-1040

2025-01-24 | E-GEOD-45757 | ExpressionAtlas

E-MTAB-8198

Project description:Functional effect of DOT1L pharmacological inhibition in ER-positive Ovarian Cancer cells

2025-01-16 | E-MTAB-8198 | ExpressionAtlas

Unraveling the mechanism of JPI-547 in human pancreatic cancer cells through transcriptome analysis.

Project description:This study aimed to elucidate the mechanism underlying the action of the dual PARP/Tankyrase inhibitor JPI-547 through RNA-sequencing. Focusing on human pancreatic cancer cell lines with either homologous recombination repair deficiency or Wnt-addiction, the investigation sought to uncover critical insights into the compound's mode of action.

2025-02-28 | GSE254997 | GEO

E-GEOD-22973

Project description:Transcription profiling of pancreatic cancer cell lines BxPC-3 and AsPC-1 stimulated with PMA to identify an invasive gene expression signature

2025-01-24 | E-GEOD-22973 | ExpressionAtlas

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data